Hasenkamp, Justin

[["dc.bibliographiccitation.firstpage","467"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","468"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Dicke, C. C."],["dc.contributor.author","Kertesz, Andras"],["dc.contributor.author","Henke, R. P."],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Wulf, Gerald G."],["dc.date.accessioned","2018-11-07T09:27:21Z"],["dc.date.available","2018-11-07T09:27:21Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1038/bmt.2012.165"],["dc.identifier.isi","000316920100026"],["dc.identifier.pmid","22964591"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30514"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0268-3369"],["dc.title","Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2476"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2480"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Hellige, Niels"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Binder, Mascha"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:43:56Z"],["dc.date.available","2020-12-10T18:43:56Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.3109/10428194.2016.1151510"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78273"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Advances in Hematology"],["dc.bibliographiccitation.lastpage","7"],["dc.bibliographiccitation.volume","2020"],["dc.contributor.author","Schmalz, Gerhard"],["dc.contributor.author","Tulani, Lulzim"],["dc.contributor.author","Busjan, Rilana"],["dc.contributor.author","Haak, Rainer"],["dc.contributor.author","Kottmann, Tanja"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Ziebolz, Dirk"],["dc.date.accessioned","2021-06-01T10:47:44Z"],["dc.date.available","2021-06-01T10:47:44Z"],["dc.date.issued","2020"],["dc.description.abstract","This retrospective pilot study aimed to detect whether remaining dental/periodontal treatment need and periodontal inflammation after dental clearance would be associated with the initial therapy outcome of adult patients with acute leukemia undergoing induction chemotherapy. Different parameters were assessed from the patients’ records: initial blood parameters, blood parameters during initial chemotherapy, leukemia/therapy related complaints, duration of fever, microbiological findings (blood and urine), as well as patients’ survival. Dental treatment need was defined as the presence of at least one carious tooth; periodontal treatment need was determined by the presence of probing depth ≥3.5 mm in at least two sextants. To reflect periodontal inflammation, the periodontal inflamed surface area (PISA) was applied. Thirty-nine patients were included. A dental treatment need of 75% and periodontal treatment need of 76% as well as an average PISA of 153.18 ± 158.09 were found. Only two associations were detected: periodontal treatment need was associated with thrombocyte count after 7 days ( p = 0.03 ), and PISA was associated with erythrocyte count three days after induction of therapy ( p = 0.01 ). It can be concluded that remaining dental and periodontal treatment need as well as periodontal inflammation after dental clearance is not associated with the outcome of induction therapy in adult patients with acute leukemia."],["dc.identifier.doi","10.1155/2020/6710906"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85702"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1687-9112"],["dc.relation.issn","1687-9104"],["dc.title","Dental and Periodontal Treatment Need after Dental Clearance Is Not Associated with the Outcome of Induction Therapy in Patients with Acute Leukemia: Results of a Retrospective Pilot Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","218"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Scandinavian Journal of Immunology"],["dc.bibliographiccitation.lastpage","229"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Borgerding, A."],["dc.contributor.author","Uhrberg, M."],["dc.contributor.author","Falk, C."],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Wulf, G."],["dc.contributor.author","Jung, W."],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Glass, B."],["dc.date.accessioned","2021-06-01T10:47:17Z"],["dc.date.available","2021-06-01T10:47:17Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1111/j.1365-3083.2007.02058.x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85548"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1365-3083"],["dc.relation.issn","0300-9475"],["dc.title","Self-tolerance of Human Natural Killer Cells Lacking Self-HLA-specific Inhibitory Receptors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","321"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Hospital Infection"],["dc.bibliographiccitation.lastpage","327"],["dc.bibliographiccitation.volume","103"],["dc.contributor.author","Fehling, P."],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Unkel, S."],["dc.contributor.author","Thalmann, I."],["dc.contributor.author","Hornig, S."],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Scheithauer, S."],["dc.date.accessioned","2020-12-10T14:25:09Z"],["dc.date.available","2020-12-10T14:25:09Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.jhin.2019.06.004"],["dc.identifier.issn","0195-6701"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72459"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Effect of gloved hand disinfection on hand hygiene before infection-prone procedures on a stem cell ward"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T10:52:41Z"],["dc.date.available","2018-11-07T10:52:41Z"],["dc.date.issued","2007"],["dc.format.extent","894A"],["dc.identifier.isi","000251100804080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49168"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","49th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Atlanta, GA"],["dc.relation.issn","0006-4971"],["dc.title","Intermediate intensity conditioning followed by allogeneic peripheral blood stem cell transplantion for treatment of high risk relapse of aggressive lymphoma. Interim analysis of the DSHNHL R3 study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","391"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","397"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Nickelsen, M."],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Claviez, Alexander"],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T10:45:48Z"],["dc.date.available","2018-11-07T10:45:48Z"],["dc.date.issued","2004"],["dc.description.abstract","In patients with poor-risk relapse of aggressive lymphoma, reduced-intensity conditioning followed by allogeneic PBSCT may have its limitations because of rapid regrowth of the tumor. We tried to address this problem by intermediate-intensity conditioning followed by allogeneic SCT. A total of 21 patients received fludarabine, busulfan and cyclophosphamide prior to allogeneic SCT. In the first 10 patients, GVHD prophylaxis by CD34+ selection of the grafts was employed (group I). The next 11 patients received nonmanipulated grafts and mycophenolat mofetil plus cyclosporinA (group II). In group I, no GVHD was observed. In contrast, patients in group II had a significant risk of acute GVHD (aGVHD) (six patients with grade II-IV acute GVHD). However, in group I, all surviving patients progressed within 9 months. In contrast, eight of nine surviving patients of group II remain in remission after a median observation time of 10.5 months (range 4-22 months). Survival differed significantly between the groups (P = 0.004). Multivariate analysis identified intensive GVHD prophylaxis as important risk factor for survival. These results support the existence of a clinically relevant GVL effect in aggressive lymphoma. T-cell depletion (or CD34 selection) of grafts is not recommended in patients with poor-risk aggressive NHL."],["dc.identifier.doi","10.1038/sj.bmt.1704600"],["dc.identifier.isi","000223351200002"],["dc.identifier.pmid","15273707"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47591"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0268-3369"],["dc.title","Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","262B"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","263B"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Borgerding, Andrea"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2018-11-07T08:57:39Z"],["dc.date.available","2018-11-07T08:57:39Z"],["dc.date.issued","2006"],["dc.identifier.isi","000242440401404"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23446"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Response to re-treatment with rituximab plus salvage-chemotherapy in refractory or relapsed aggressive Non-Hodgkin's lymphoma."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","692982-1"],["dc.bibliographiccitation.journal","Case reports in hematology"],["dc.bibliographiccitation.lastpage","692982-3"],["dc.bibliographiccitation.volume","2011"],["dc.contributor.author","Zaenker, Stephan"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Truemper, Lorenz"],["dc.contributor.author","Wulf, Gerald"],["dc.date.accessioned","2019-07-09T11:54:03Z"],["dc.date.available","2019-07-09T11:54:03Z"],["dc.date.issued","2011"],["dc.description.abstract","Granulocytic sarcoma (GS) represents a rare type of extramedullar manifestation from the acute myeloid leukaemia (AML). We report the case of a patient with recurrences of AML M4eo leukaemia in the uterus and the small intestine at 3 and 5 years, respectively, after matched related peripheral blood stem cell transplantation (PBSCT). The patient underwent the withdrawal of immunosuppression, hysterectomy, and local irradiation at first relapse, as well as systemic chemotherapy and donor lymphocyte infusions at second recurrence, inducing a second and third complete remission, respectively. At year six after transplantation, the patient experienced disease progression by meningeosis leukaemia to which she succumbed despite intrathecal chemotherapy. Following allogeneic stem cell transplantation, awareness for atypical manifestations of granulocytic sarcoma appears prudent, the cellular immunotherapy should aim at immunological disease control."],["dc.identifier.doi","10.1155/2011/692982"],["dc.identifier.pmid","22937311"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8385"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60560"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-6579"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Granulocytic Sarcoma by AML M4eo (inv16) after Allogeneic Stem Cell Transplantation without Bone Marrow Involvement."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]